Achieving tissue-level perfusion in the setting of acute myocardial infarction

American Journal of Cardiology

Volumn 85, Issue 8 SUPPL. 1, 2000, Pages 39-46

  Mukherjee, Debabrata ^a   Moliterno, David J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; BLOOD FLOWMETRY; FIBRINOLYTIC THERAPY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HUMAN; PRIORITY JOURNAL; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0034720134     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)00818-3     Document Type: Article

References (58)

1. Topol EJ, Morris DC, Smalling RW, Schumacher RR, Taylor CR, Nishikawa A, Liberman HA, Collen D, Tufte ME, Grossbard EB, et al. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. J Am Coll Cardiol 1987;9:1205-1213.
2. Neuhaus KL, von Essen R Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the r-tPA-APSAC patency study (TAPS). J Am Coll Cardiol 1992;19:885-891.
3. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-1628.
4. Topol E. GUSTO IV (SPEED). American Heart Association. Dallas, Texas, 1998.
5. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997;95:846-854.
6. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: Phase I findings. N Engl J Med 1985;312:932-936.
7. Lincoff A.M., Topol E.J., Califf R.M., Sigmon K.N., Lee K.L., Ohman E.M., Rosenschein U., Ellis S.G. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Am J Cardiol. 75:1995;871-876.
8. Gibson CM, Cannon CP, Piana RN, Breall JA, Sharaf B, Flatley M, Alexander B, Diver DJ, McCabe CH, Flaker GC, et al. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1995;25:582-589.
9. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995;91:1923-1928.
10. Tan W.A., Moliterno D.J. TIMI flow and surrogate end points What you see is not always what you get . Am Heart J. 136:1998;570-573.
11. Gassler J.P., Topol E.J. Reperfusion revisited beyond TIMI 3 flow . Clin Cardiol. 22:1999;IV20-IV29.
12. El-Maraghi N., Genton E. The relevance of platelet and fibrin thromboembolism of the coronary microcirculation, with special reference to sudden cardiac death. Circulation. 62:1980;936-944.
13. Kiyak J.H., Zerbino D.D. Pathogenesis and morphogenesis of microcirculatory disorders in myocardial infarction clinical and ultrastructural examination . Pol J Pathol. 47:1996;27-32.
14. Minamino T., Kitakaze M., Asanuma H., Tomiyama Y., Shiraga M., Sato H., Ueda Y., Funaya H., Kuzuya T., Matsuzawa Y., Hori M. Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J Clin Invest. 101:1998;1643-1653.
15. Jafar J.J., Menoni R., Feinberg H., LeBreton G., Crowell R.M. Selective platelet deposition during focal cerebral ischemia in cats. Stroke. 20:1989;664-667.
16. Willerson J.T., Golino P., Eidt J., Campbell W.B., Buja L.M. Specific platelet mediators and unstable coronary artery lesions experimental evidence and potential clinical implications . Circulation. 80:1989;198-205.
17. Kloner R.A., Ganote C.E., Jennings R.B. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 54:1974;1496-1508.
18. Kloner R.A., Rude R.E., Carlson N., Maroko P.R., DeBoer L.W., Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion Which comes first? Circulation. 62:1980;945-952.
19. Dreyer W.J., Michael L.H., West M.S., Smith C.W., Rothlein R., Rossen R.D., Anderson D.C., Entman M.L. Neutrophil accumulation in ischemic canine myocardium insights into time course, distribution, and mechanism of localization during early reperfusion . Circulation. 84:1991;400-411.
20. Engler R.L., Dahlgren M.D., Morris D.D., Peterson M.A., Schmid-Schonbein G.W. Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol. 251:1986;H314-H323.
21. Go L., Murry C.E., Richard V.J., Weischedel G.R., Jennings R.B., Reimer K.A. Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury. Am J Physiol. 255:1988;H1188-H1198.
22. Przyklenk K., Kloner R.A. "Reperfusion injury" by oxygen-derived free radicals? Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile function, coronary microvasculature, and regional myocardial blood flow. Circ Res. 64:1989;86-96.
23. Myers M.L., Bolli R., Lekich R.F., Hartley C.J., Roberts R. Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia. Circulation. 72:1985;915-921.
24. Wall TC, Califf RM, Blankenship J, Talley JD, Tannenbaum M, Schwaiger M, Gacioch G, Cohen MD, Sanz M, Leimberger JD, et al. Intravenous Fluosol in the treatment of acute myocardial infarction: results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. Circulation 1994;90:114-120.
25. Flaherty JT, Pitt B, Gruber JW, Heuser RR, Rothbaum DA, Burwell LR, George BS, Kereiakes DJ, Deitchman D, Gustafson N, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994;89:1982-1991.
26. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ, Lee KL, et al. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction: Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. J Am Coll Cardiol 1989;14:877-884.
27. Saeed M., van Dijke C.F., Mann J.S., Wendland M.F., Rosenau W., Higgins C.B., Brasch R.C. Histologic confirmation of microvascular hyperpermeability to macromolecular MR contrast medium in reperfused myocardial infarction. J Magn Reson Imaging. 8:1998;561-567.
28. Vedrinne J.M., Vedrinne C., Bompard D., Lehot J.J., Boissel J.P., Champsaur G. Myocardial protection during coronary artery bypass graft surgery a randomized, double-blind, placebo-controlled study with trimetazidine . Anesth Analg. 82:1996;712-718.
29. Gibson C., Cannon C., Murphy S., Ryan K., Mesley R., Marble S., McCabe C., Van de Werf F., Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 101:2000;125-130.
30. Ito H., Okamura A., Iwakura K., Masuyama T., Hori M., Takiuchi S., Negoro S., Nakatsuchi Y., Taniyama Y., Higashino Y., Fujii K., Minamino T. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 93:1996;1993-1999.
31. Ragosta M., Camarano G., Kaul S., Powers E.R., Sarembock I.J., Gimple L.W. Microvascular integrity indicates myocellular viability in patients with recent myocardial infarction new insights using myocardial contrast echocardiography . Circulation. 89:1994;2562-2569.
32. Ito H., Tomooka T., Sakai N., Yu H., Higashino Y., Fujii K., Masuyama T., Kitabatake A., Minamino T. Lack of myocardial perfusion immediately after successful thrombolysis a predictor of poor recovery of left ventricular function in anterior myocardial infarction . Circulation. 85:1992;1699-1705.
33. Porter T.R., Xie F., Kilzer K. Intravenous perfluoropropane-exposed sonicated dextrose albumin produces myocardial ultrasound contrast that correlates with coronary blood flow. J Am Soc Echocardiogr. 8:1995;710-718.
34. Porter T., Li S., Oster R., Deligonul U. Implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction. Am J Cardiol. 82:1998;1173-1177.
35. Vanhaecke J., Flameng W., Borgers M., Jang I.K., Van de Werf F., De Geest H. Evidence for decreased coronary flow reserve in viable postischemic myocardium. Circ Res. 67:1990;1201-1210.
36. Iwakura K., Ito H., Takiuchi S., Taniyama Y., Nakatsuchi Y., Negoro S., Higashino Y., Okamura A., Masuyama T., Hori M., Fujii K., Minamino T. Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction. Circulation. 94:1996;1269-1275.
37. Nakamura M., Tsunoda T., Wakatsuki T., Ui K., Degawa T., Yabuki S., Yamaguchi T. Distal coronary flow velocity immediately after direct angioplasty for acute myocardial infarction. Am Heart J. 132:1996;251-257.
38. Mak KH, Neumann FJ, Blasini MR, Schmitt MC, Alt ME, Dirschinger MJ, Gawaz MM, Kastrati MA, Schomig MA. Recovery of coronary flow and left ventricular function after abciximab (letter). Circulation 1999;100:e110.
39. Neumann F.J., Blasini R., Schmitt C., Alt E., Dirschinger J., Gawaz M., Kastrati A., Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 98:1998;2695-2701.
40. Wu K.C., Zerhouni E.A., Judd R.M., Lugo-Olivieri C.H., Barouch L.A., Schulman S.P., Blumenthal R.S., Lima J.A. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 97:1998;765-772.
41. Schofer J., Montz R., Mathey D.G. Scintigraphic evidence of the "no reflow" phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol. 5:1985;593-598.
42. Kondo M., Nakano A., Saito D., Shimmo Y. Assessment of "microvascular no-reflow phenomenon" using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol. 32:1998;898-903.
43. Schroder R., Wegscheider K., Schroder K., Dissmann R., Meyer-Sabellek W. Extent of early ST segment elevation resolution a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial . J Am Coll Cardiol. 26:1995;1657-1664.
44. Langer A., Krucoff M.W., Klootwijk P., Veldkamp R., Simoons M.L., Granger C., Califf R.M., Armstrong P.W. Noninvasive assessment of speed and stability of infarct-related artery reperfusion results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries . J Am Coll Cardiol. 25:1995;1552-1557.
45. de Lemos J.A., Antman E.M., Gibson C.M., McCabe C.H., Giugliano R.P., Murphy S.A., Coulter S.A., Anderson K., Scherer J., Frey M.J., Van Der Wieken R., Van de Werf F., Braunwald E. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction observations from the TIMI 14 trial . Circulation. 101:2000;239-243.
46. Neumann F.J., Kosa I., Dickfeld T., Blasini R., Gawaz M., Hausleiter J., Schwaiger M., Schomig A. Recovery of myocardial perfusion in acute myocardial infarction after successful balloon angioplasty and stent placement in the infarct-related coronary artery. J Am Coll Cardiol. 30:1997;1270-1276.
47. Ito H., Iwakura K., Oh H., Masuyama T., Hori M., Higashino Y., Fujii K., Minamino T. Temporal changes in myocardial perfusion patterns in patients with reperfused anterior wall myocardial infarction their relation to myocardial viability . Circulation. 91:1995;656-662.
48. Brochet E., Czitrom D., Karila-Cohen D., Seknadji P., Faraggi M., Benamer H., Aubry P., Steg P.G., Assayag P. Early changes in myocardial perfusion patterns after myocardial infarction relation with contractile reserve and functional recovery . J Am Coll Cardiol. 32:1998;2011-2017.
49. Sakuma T., Hayashi Y., Sumii K., Imazu M., Yamakido M. Prediction of short- and intermediate-term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization. J Am Coll Cardiol. 32:1998;890-897.
50. Ito H., Maruyama A., Iwakura K., Takiuchi S., Masuyama T., Hori M., Higashino Y., Fujii K., Minamino T. Clinical implications of the "no reflow" phenomenon a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction . Circulation. 93:1996;223-228.
51. Rawitscher D., Levin T.N., Cohen I., Feldman T. Rapid reversal of no-reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn. 42:1997;187-190.
52. Sakata Y., Kodama K., Komamura K., Lim Y.J., Ishikura F., Hirayama A., Kitakaze M., Masuyama T., Hori M. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J. 133:1997;616-621.
53. Ishihara M., Sato H., Tateishi H., Kawagoe T., Shimatani Y., Kurisu S., Sakai K. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J. 132:1996;959-963.
54. Piana R.N., Paik G.Y., Moscucci M., Cohen D.J., Gibson C.M., Kugelmass A.D., Carrozza J.P. Jr, Kuntz R.E., Baim D.S. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation. 89:1994;2514-2518.
55. Abbo K.M., Dooris M., Glazier S., O'Neill W.W., Byrd D., Grines C.L., Safian R.D. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol. 75:1995;778-782.
56. Taniyama Y., Ito H., Iwakura K., Masuyama T., Hori M., Takiuchi S., Nishikawa N., Higashino Y., Fujii K., Minamino T. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol. 30:1997;1193-1199.
57. Olafsson B., Forman M.B., Puett D.W., Pou A., Cates C.U., Friesinger G.C., Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine importance of the endothelium and the no-reflow phenomenon . Circulation. 76:1987;1135-1145.
58. Mahaffey K.W., Puma J.A., Barbagelata N.A., DiCarli M.F., Leesar M.A., Browne K.F., Eisenberg P.R., Bolli R., Casas A.C., Molina-Viamonte V., Orlandi C., Blevins R., Gibbons R.J., Califf R.M., Granger C.B. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial . J Am Coll Cardiol. 34:1999;1711-1720.